Department of Pharmacology, Southern Illinois University School of Medicine, Springfield, IL 62702, USA.
Curr Top Med Chem. 2011;11(17):2192-209. doi: 10.2174/156802611796904834.
The transient receptor potential vanilloid 1 (TRPV1) channel has been a topic of great interest, since its discovery in 1997. It is a homotetrameric non-selective cation channel predominantly expressed in a population of sensory neurons and its involvement in different modalities of pain has been extensively studied. However, TRPV1 has also been shown to be expressed in non-sensory neurons and non-neuronal cells. TRPV1 is considered as a potential target for drug development, based on its tissue distribution and its role in physiological functions. Here, we summarize the evidences for disease-related alterations in TRPV1 expression and function and review the current perspectives for the therapeutic potential of TRPV1 agonists and antagonists in the treatment of a wide range of diseases.
瞬时受体电位香草素 1（TRPV1）通道自 1997 年发现以来一直是一个备受关注的话题。它是一种四聚体非选择性阳离子通道，主要表达在感觉神经元群体中，其在不同类型疼痛中的作用已得到广泛研究。然而，TRPV1 也已被证明存在于非感觉神经元和非神经元细胞中。基于其组织分布和在生理功能中的作用，TRPV1 被认为是药物开发的潜在靶点。在这里，我们总结了 TRPV1 表达和功能与疾病相关的改变的证据，并回顾了 TRPV1 激动剂和拮抗剂在治疗广泛疾病中的治疗潜力的当前观点。
